Enrique Conde

Enrique Conde

Auto-generated profile, based on publicly available information

Enrique Conde

Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2017 in Cancer Research
Verified
Journal Article
Open access
PDF file
SFSarita M. Fernandez-Poma
Sarita M. Fernandez-Poma
DBDiego Salas Benito
Diego Salas Benito
TLTeresa Lozano
Teresa Lozano
NCNoelia Casares
Noelia Casares
JRJosé-Ignacio Riezu-Boj
José-Ignacio Riezu-Boj
SHSandra Hervas-Stubbs
Sandra Hervas-Stubbs
Recent studies have found that tumor-infiltrating lymphocytes (TIL) expressing PD-1 can recognize autologous tumor cells, suggesting that cells derived from PD-1+ TILs can be used in adoptive T-cell therapy (ACT). However, no study thus far has evaluated the antitumor activity of PD-1–selected TILs in vivo. In two mouse models of solid tumors, we show that PD-1 allows identification and isolation of tumor-specific TILs without previous knowledge of their antigen specificities. Importantly, despite the high proportion of tumor-reactive T cells present in bulk CD8 TILs before expansion, only T-cell products derived from sorted PD-1+, but not from PD-1− or bulk CD8 TILs, specifically recognized tumor cells. The fold expansion of PD-1+ CD8 TILs was 10 times lower than that of PD-1− cells, suggesting that outgrowth of PD-1− cells was the limiting factor in the tumor specificity of cells derived from bulk CD8 TILs. The highly differentiated state of PD-1+ cells was likely the main cause hampering ex vivo expansion of this subset. Moreover, PD-1 precisely identified marrow-infiltrating, myeloma-specific T cells in a mouse model of multiple myeloma. In vivo, only cells expanded from PD-1+ CD8 TILs contained tumor progression, and their efficacy was enhanced by PDL-1 blockade. Overall, our data provide a rationale for the use of PD-1–selected TILs in ACT. Cancer Res; 77(13); 3672–84. ©2017 AACR.

5 January 2021 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
DBDiego Salas Benito
Diego Salas Benito
ECEnrique Conde
Enrique Conde
ITIbon Tamayo-Uria
Ibon Tamayo-Uria
UMUxua Mancheño
Uxua Mancheño
EEEdurne Elizalde
Edurne Elizalde
SHSandra Hervas-Stubbs
Sandra Hervas-Stubbs
Background: Adoptive immunotherapy with tumour-infiltrating lymphocytes (TIL) may benefit from the use of selective markers, such as PD-1, for tumour-specific T-cell enrichment, and the identification of predictive factors that help identify those patients capable of rendering tumour-reactive TILs. We have investigated this in ovarian cancer (OC) patients as candidates for TIL therapy implementation.Methods: PD-1−and PD-1+CD8 TILs were isolated from ovarian tumours and expanded cells were tested against autologous tumour cells. Baseline tumour samples were examined using flow cytometry, multiplexed immunofluorescence and Nanostring technology, for gene expression analyses, as well as a next-generation sequencing gene panel, for tumour mutational burden (TMB) calculation.Results: Tumour-reactive TILs were detected in half of patients and were exclusively present in cells derived from the PD-1+fraction. Importantly, a high TIL density in the fresh tumour, the presence of CD137+cells within the PD-1+CD8+TIL subset and their location in the tumour epithelium, together with a baseline T-cell-inflamed genetic signature and/or a high TMB, are features that identify patients rendering tumour-reactive TIL products.Conclusion: We have demonstrated that PD-1 identifies ovarian tumour-specific CD8 TILs and has uncovered predictive factors that identify OC patients who are likely to render tumour-specific cells from PD-1+TILs.